凝血检查在急性髓细胞白血病诊治临床意义研究  

The Clinical Significance of Coagulation Test in the Diagnosis and Treatment of Acute Myeloid Leukemia

作　　者：代文芳 DAI Wenfang(Department of Laboratory Medicine,the First People's Hospital of Qujing City,Qujing,Yunnan Province,655000 China)

机构地区：[1]云南省曲靖市第一人民医院检验科,云南曲靖655000

出　　处：《中外医疗》2021年第23期181-184,共4页China & Foreign Medical Treatment

摘　　要：目的探讨急性髓细胞白血病实施凝血检查的临床诊断意义。方法简单随机选取2017年7月—2019年7月在该院接受急性髓细胞白血病治疗的100例患者,设为白血病组,选取同期在该院接受健康体检的100名健康人,设为健康组,两组患者均接受凝血指标检查,比较两组凝血功能指标的变化、炎性因子水平与血小板参数。结果白血病组血浆纤维蛋白原(FIB)(4.34±0.52)g/L、血浆D-二聚体(D-D)(1.28±0.15)mg/L、凝血酶原时间(PT)(12.77±1.22)s、活化部分凝血活酶时间(APTT)(36.74±2.18)s、凝血酶时间(TT)(17.83±1.17)s水平均高于健康组,差异有统计学意义(t=8.329、49.975、7.341、21.595、74.740,P<0.001);凝血酶原时间国际标准化比值(PT-INR)(0.95±0.08)与抗凝血酶(ATⅢ)(71.34±8.52)%均低于健康组,差异有统计学意义(t=2.491、17.293,P<0.001);白血病组超敏C-反应蛋白(HS-CRP)(46.82±6.33)mg/L、降钙素原(PCT)(0.47±0.06)μg/L与CD64阳性率(38.03±4.14)%均高于健康组,差异有统计学意义(t=63.077、60.083、71.320,P<0.001);白血病组血小板平均体积(MPV)(12.59±1.41)fl、血小板分布宽度(PDW)(5.33±0.72)%、血小板计数(PLT)(70.52±25.65)×10^(9)/L、大血小板比率(P-LCR)(11.48±3.28)%水平均比健康组差,差异有统计学意义(t=24.475、32.227、41.831、52.444,P<0.001)。结论凝血功能指标可以有效测定急性髓细胞白血病与健康人之间的区别,通过凝血功能指标、炎性因子水平与血小板参数的数据变化可以有效判定患者的病情,因此动态监测凝血功能指标、炎性因子水平与血小板参数的变化可以为临床医生诊断病情提供依据,为后期的治疗提供参考。Objective The clinical diagnostic significance of blood coagulation test for acute myeloid leukemia.Methods From July 2017 to July 2019,100 patients who were treated for acute myeloid leukemia in the hospital were simply and randomly selected as the leukemia group,and 100 healthy people who received physical examinations in the hospital during the same period were selected as the healthy group.Two groups of patients All patients were checked for coagulation index,and the changes of coagulation function index,inflammatory factor levels and platelet parameters were compared between the two groups.Results In the leukemia group,plasma fibrinogen(FIB)(4.34±0.52)g/L,plasma D-dimer(DD)(1.28±0.15)mg/L,prothrombin time(PT)(12.77±1.22)s,activated partial thromboplastin time(APTT)(36.74±2.18)s,thrombin time(TT)(17.83±1.17)s were higher than the healthy group,the difference was statistically significant(t=8.329,49.975,7.341,21.595,74.740,P<0.001);prothrombin time international normalized ratio(PT-INR)(0.95±0.08)and antithrombin(ATⅢ)(71.34±8.52)%were lower than the healthy group,the difference was statistically significant(t=2.491,17.293,P<0.001);hypersensitive C-reactive protein(HS-CRP)(46.82±6.33)mg/L,procalcitonin(PCT)(0.47±0.06)μg/L in leukemia group and the positive rates of CD64(38.03±4.14)%were higher than those of the healthy group,and the difference was statistically significant(t=63.077,60.083,71.320,P<0.001);the mean platelet volume(MPV)of the leukemia group(12.59±1.41)fl,platelet distribution width(PDW)(5.33±0.72)%,platelet count(PLT)(70.52±25.65)×10^(9)/L,large platelet ratio(P-LCR)(11.48±3.28)%level was worse than the healthy group,the difference was statistically significant(t=24.475,32.227,41.831,52.444,P<0.001).Conclusion The coagulation function index can effectively determine the difference between acute myeloid leukemia and healthy people.The patient’s condition can be effectively determined through the data changes of coagulation function index,inflammatory factor level and platelet pa

关 键 词：凝血检查 急性髓细胞白血病 临床诊断 

分 类 号：R4[医药卫生—临床医学]